RCUS Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 13.80%

Insider Buying (Last 12 Months): $339,452,595.00

Insider Selling (Last 12 Months): $3,417,282.87

Arcus Biosciences Insider Trading History Chart

Arcus Biosciences Share Price & Price History

^$14.84

+0.30 (1.20%)

As of 04/18/2024 01:00 AM ET

Days: 30 | 90 | 365

New crypto project uncovers 2,050% in 65 days

From InvestorPlace | Ad

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

Arcus Biosciences Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/27/2024	Jennifer Jarrett	COO	Sell	11,551	$17.55	$202,720.05	215,253
3/18/2024	Jennifer Jarrett	COO	Sell	13,449	$17.92	$241,006.08	226,804
2/26/2024	Jennifer Jarrett	COO	Sell	24,555	$20.07	$492,818.85	274,323
2/26/2024	Juan C. Jaen	President	Sell	3,900	$20.06	$78,234.00	1,211,365
1/29/2024	Gilead Sciences, Inc.	Major Shareholder	Buy	15,238,095	$21.00	$319,999,995.00	30,061,124
1/2/2024	Juan C. Jaen	President	Sell	6,975	$20.09	$140,127.75	1,215,265
1/2/2024	Robert C Goeltz II	CFO	Sell	2,004	$20.00	$40,080.00	51,831
12/22/2023	Jennifer Jarrett	COO	Sell	21,521	$17.76	$382,212.96	258,878
9/22/2023	Jennifer Jarrett	COO	Sell	21,369	$19.99	$427,166.31	302,691
7/28/2023	Jennifer Jarrett	COO	Sell	45,000	$20.25	$911,250.00	336,566
7/3/2023	Alexander Azoy	CAO	Sell	1,018	$20.41	$20,777.38	11,596
6/28/2023	Gilead Sciences, Inc.	Major Shareholder	Buy	1,010,000	$19.26	$19,452,600.00	14,823,029
6/22/2023	Jennifer Jarrett	COO	Sell	12,437	$19.12	$237,795.44	381,566
6/16/2023	Jennifer Jarrett	COO	Sell	12,563	$19.35	$243,094.05	394,003
3/16/2023	Jennifer Jarrett	COO	Sell	8,729	$16.81	$146,734.49	406,217
1/26/2023	Jennifer Jarrett	COO	Sell	300	$23.56	$7,068.00	416,546
12/16/2022	Carolyn C Tang	General Counsel	Sell	2,523	$30.75	$77,582.25	28,584
12/16/2022	Jennifer Jarrett	COO	Sell	16,482	$30.75	$506,821.50	147,609
12/16/2022	Juan C. Jaen	President	Sell	4,436	$30.75	$136,407.00	218,258
12/16/2022	Robert C Goeltz II	CFO	Sell	2,453	$30.75	$75,429.75	11,566
12/16/2022	Terry J. Rosen	CEO	Sell	13,043	$30.75	$401,072.25	242,173
9/16/2022	Jennifer Jarrett	COO	Sell	12,677	$26.28	$333,151.56	130,942
6/16/2022	Carolyn C Tang	General Counsel	Sell	1,400	$20.72	$29,008.00	25,431
6/16/2022	Jennifer Jarrett	COO	Sell	6,081	$20.72	$125,998.32	125,233
6/16/2022	Juan C. Jaen	President	Sell	2,333	$20.72	$48,339.76	212,574
6/16/2022	Terry J. Rosen	CEO	Sell	4,241	$20.72	$87,873.52	232,329
3/16/2022	Jennifer Jarrett	COO	Sell	9,617	$31.62	$304,089.54
12/20/2021	Jennifer Jarrett	COO	Sell	34,822	$41.48	$1,444,416.56
12/16/2021	Carolyn C Tang	General Counsel	Sell	487	$39.82	$19,392.34
12/16/2021	Jennifer Jarrett	COO	Sell	5,560	$39.82	$221,399.20
12/16/2021	Juan C. Jaen	President	Sell	865	$39.82	$34,444.30
12/16/2021	Robert C Goeltz II	CFO	Sell	485	$39.83	$19,317.55
12/16/2021	Terry J. Rosen	CEO	Sell	2,299	$39.82	$91,546.18
9/20/2021	Jennifer Jarrett	COO	Sell	30,634	$35.18	$1,077,704.12
6/16/2021	Carolyn C. Tang	General Counsel	Sell	1,309	$24.16	$31,625.44
6/4/2021	Jennifer Jarrett	COO	Sell	1,044	$24.91	$26,006.04
4/23/2021	Yasunori Kaneko	Director	Buy	4,133	$31.37	$129,652.21	6,717

The A.I. story nobody is telling you (Read ASAP)

From TradeSmith | Ad

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

SEC Filings (Institutional Ownership Changes) for Arcus Biosciences (NYSE:RCUS)

92.89% of Arcus Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Arcus Biosciences Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/18/2024	Allspring Global Investments Holdings LLC	12,940	$0.24M	0.0%	+9.2%	0.014%
4/18/2024	Diversified Trust Co	12,078	$0.23M	0.0%	N/A	0.013%
4/5/2024	GAMMA Investing LLC	2,427	$46K	0.0%	+51.6%	0.003%
3/22/2024	PNC Financial Services Group Inc.	1,507	$29K	0.0%	-61.4%	0.002%
3/11/2024	Vanguard Group Inc.	4,680,716	$89.40M	0.0%	+4.2%	5.152%
3/1/2024	Goldman Sachs Group Inc.	592,291	$11.31M	0.0%	+0.7%	0.652%
2/16/2024	Price T Rowe Associates Inc. MD	32,858	$0.63M	0.0%	+5.3%	0.044%
2/16/2024	GSA Capital Partners LLP	90,873	$1.74M	0.1%	+329.9%	0.121%
2/16/2024	Public Employees Retirement System of Ohio	10,787	$0.21M	0.0%	+439.4%	0.014%
2/15/2024	Legal & General Group Plc	148,930	$2.85M	0.0%	-0.8%	0.199%
2/15/2024	Barclays PLC	202,893	$3.88M	0.0%	-56.9%	0.271%
2/15/2024	Vanguard Group Inc.	4,680,716	$89.40M	0.0%	+4.2%	6.253%
2/15/2024	Nuveen Asset Management LLC	133,447	$2.55M	0.0%	-71.2%	0.178%
2/15/2024	Octagon Capital Advisors LP	1,868,000	$35.68M	5.7%	-5.1%	2.495%
2/15/2024	Price T Rowe Associates Inc. MD	32,858	$0.63M	0.0%	+5.3%	0.044%
2/15/2024	Profund Advisors LLC	43,165	$0.82M	0.0%	-15.5%	0.058%
2/15/2024	Public Sector Pension Investment Board	111,846	$2.14M	0.0%	+68.7%	0.149%
2/15/2024	Parkman Healthcare Partners LLC	247,664	$4.73M	0.7%	+20.7%	0.331%
2/15/2024	Gilder Gagnon Howe & Co. LLC	139,170	$2.66M	0.0%	-41.7%	0.186%
2/15/2024	Granahan Investment Management LLC	230,777	$4.41M	0.1%	+18.0%	0.308%
2/14/2024	Royal Bank of Canada	5,229	$100K	0.0%	+28,950.0%	0.007%
2/14/2024	Point72 Asset Management L.P.	768,750	$14.68M	0.0%	+17,148.1%	1.027%
2/14/2024	Pennant Investors LP	23,700	$0.45M	0.1%	N/A	0.032%
2/14/2024	Balyasny Asset Management L.P.	515,453	$9.85M	0.0%	+11.0%	0.689%
2/14/2024	Sectoral Asset Management Inc.	97,435	$1.86M	0.8%	-74.0%	0.130%
2/13/2024	Northern Trust Corp	524,689	$10.02M	0.0%	+1.4%	0.701%
2/13/2024	Tower Research Capital LLC TRC	2,514	$48K	0.0%	-47.4%	0.003%
2/13/2024	Goldman Sachs Group Inc.	592,291	$11.31M	0.0%	+0.7%	0.791%
2/13/2024	Rafferty Asset Management LLC	251,404	$4.80M	0.0%	-14.1%	0.336%
2/13/2024	NEOS Investment Management LLC	11,141	$0.21M	0.0%	N/A	0.015%
2/13/2024	KBC Group NV	1,952	$37K	0.0%	-51.5%	0.003%
2/13/2024	Campbell & CO Investment Adviser LLC	62,894	$1.20M	0.1%	N/A	0.084%
2/13/2024	California State Teachers Retirement System	51,988	$0.99M	0.0%	-3.1%	0.069%
2/12/2024	Alpha DNA Investment Management LLC	28,690	$0.55M	0.2%	+11.6%	0.038%
2/12/2024	Capstone Investment Advisors LLC	10,643	$0.20M	0.0%	N/A	0.014%
2/12/2024	Decheng Capital LLC	869,790	$16.61M	4.6%	N/A	1.162%
2/12/2024	Allianz Asset Management GmbH	23,300	$0.45M	0.0%	-37.0%	0.031%
2/12/2024	Cape Investment Advisory Inc.	4,045	$77K	0.0%	N/A	0.005%
2/9/2024	US Bancorp DE	8,661	$0.17M	0.0%	+353.5%	0.012%
2/9/2024	Quest Partners LLC	4,013	$77K	0.0%	N/A	0.005%
2/9/2024	Trexquant Investment LP	43,537	$0.83M	0.0%	-44.6%	0.058%
2/9/2024	UBS Group AG	162,484	$3.10M	0.0%	+182.4%	0.217%
2/9/2024	PNC Financial Services Group Inc.	1,507	$29K	0.0%	-61.4%	0.002%
2/9/2024	Norges Bank	79,824	$1.53M	0.0%	N/A	0.107%
2/8/2024	Panagora Asset Management Inc.	228,996	$4.37M	0.0%	+130.6%	0.306%
2/8/2024	Massachusetts Financial Services Co. MA	56,346	$1.08M	0.0%	-3.1%	0.075%
2/7/2024	Principal Financial Group Inc.	332,814	$6.36M	0.0%	+1.0%	0.445%
2/7/2024	Dimensional Fund Advisors LP	1,594,609	$30.46M	0.0%	+11.0%	2.130%
2/7/2024	BNP Paribas Financial Markets	110,366	$2.11M	0.0%	+32.5%	0.147%
2/7/2024	Teacher Retirement System of Texas	11,155	$0.21M	0.0%	-17.3%	0.015%
2/7/2024	E Fund Management Co. Ltd.	13,501	$0.26M	0.0%	-10.2%	0.018%
2/6/2024	Charles Schwab Investment Management Inc.	472,182	$9.02M	0.0%	+2.5%	0.631%
2/6/2024	Amalgamated Bank	21,027	$0.40M	0.0%	-4.4%	0.028%
2/6/2024	Swiss National Bank	95,396	$1.82M	0.0%	-8.6%	0.127%
2/5/2024	Victory Capital Management Inc.	104,413	$1.99M	0.0%	+53.3%	0.139%
2/5/2024	Mach 1 Financial Group LLC	25,314	$0.48M	0.2%	+11.2%	0.034%
2/1/2024	Yousif Capital Management LLC	27,094	$0.52M	0.0%	-5.6%	0.036%
2/1/2024	GAMMA Investing LLC	1,601	$31K	0.0%	N/A	0.002%
2/1/2024	Handelsbanken Fonder AB	12,800	$0.24M	0.0%	N/A	0.017%
1/30/2024	Zurcher Kantonalbank Zurich Cantonalbank	18,883	$0.36M	0.0%	+37.5%	0.025%
1/30/2024	Strs Ohio	8,300	$0.16M	0.0%	+245.8%	0.011%
1/29/2024	Louisiana State Employees Retirement System	27,000	$0.52M	0.0%	N/A	0.036%
1/25/2024	Allspring Global Investments Holdings LLC	11,850	$0.23M	0.0%	+27.0%	0.016%
1/24/2024	Mirae Asset Global Investments Co. Ltd.	30,654	$0.59M	0.0%	-2.7%	0.041%
1/17/2024	Assenagon Asset Management S.A.	47,253	$0.90M	0.0%	N/A	0.063%
1/12/2024	SG Americas Securities LLC	20,568	$0.39M	0.0%	N/A	0.027%
1/10/2024	Nordea Investment Management AB	205,428	$3.95M	0.0%	-3.0%	0.274%
1/5/2024	Exchange Traded Concepts LLC	6,816	$0.13M	0.0%	+34.0%	0.009%
12/19/2023	Public Employees Retirement System of Ohio	2,000	$36K	0.0%	N/A	0.003%
12/18/2023	Vanguard Group Inc.	4,493,818	$80.66M	0.0%	+1.4%	6.003%
12/7/2023	Hudson Bay Capital Management LP	80,000	$1.44M	0.0%	-30.4%	0.107%
12/6/2023	Citigroup Inc.	145,729	$2.62M	0.0%	+20.8%	0.195%
11/30/2023	American Century Companies Inc.	457,695	$8.22M	0.0%	+3.0%	0.611%
11/24/2023	Deutsche Bank AG	26,854	$0.48M	0.0%	+14.4%	0.036%
11/22/2023	Public Sector Pension Investment Board	66,302	$1.19M	0.0%	-29.0%	0.089%
11/21/2023	Comerica Bank	24,622	$0.44M	0.0%	+2,827.7%	0.033%
11/17/2023	Jacobs Levy Equity Management Inc.	139,059	$2.50M	0.0%	N/A	0.186%
11/16/2023	Tudor Investment Corp Et Al	28,173	$0.51M	0.0%	N/A	0.038%
11/16/2023	Public Employees Retirement System of Ohio	2,000	$36K	0.0%	N/A	0.003%
11/15/2023	The Manufacturers Life Insurance Company	26,806	$0.48M	0.0%	-47.6%	0.036%
11/15/2023	GSA Capital Partners LLP	21,138	$0.38M	0.0%	N/A	0.028%
11/15/2023	Sectoral Asset Management Inc.	375,456	$6.74M	1.3%	+5.9%	0.502%
11/15/2023	Seven Eight Capital LP	16,265	$0.29M	0.0%	N/A	0.022%
11/15/2023	Legal & General Group Plc	150,195	$2.70M	0.0%	+3.5%	0.201%
11/15/2023	Alps Advisors Inc.	54,951	$0.99M	0.0%	+2.3%	0.073%
11/15/2023	Ameriprise Financial Inc.	1,579,924	$28.36M	0.0%	+6.9%	2.111%
11/14/2023	Lazard Asset Management LLC	3,960	$71K	0.0%	N/A	0.005%
11/14/2023	Schonfeld Strategic Advisors LLC	142,900	$2.57M	0.0%	-21.9%	0.191%
11/14/2023	California State Teachers Retirement System	53,638	$0.96M	0.0%	-4.4%	0.072%
11/14/2023	Tower Research Capital LLC TRC	4,784	$86K	0.0%	-35.2%	0.006%
11/14/2023	Trexquant Investment LP	78,637	$1.41M	0.0%	N/A	0.105%
11/14/2023	Profund Advisors LLC	51,071	$0.92M	0.1%	-9.4%	0.068%
11/13/2023	Algert Global LLC	72,018	$1.29M	0.1%	+15.8%	0.096%
11/13/2023	Northern Trust Corp	517,484	$9.29M	0.0%	+2.0%	0.691%
11/13/2023	Dark Forest Capital Management LP	38,224	$0.69M	0.1%	N/A	0.051%
11/13/2023	Invesco Ltd.	232,804	$4.18M	0.0%	-6.6%	0.311%
11/13/2023	FMR LLC	4,780,052	$85.80M	0.0%	+4.9%	6.385%
11/13/2023	Nordea Investment Management AB	211,784	$3.79M	0.0%	+12.9%	0.283%
11/13/2023	Rafferty Asset Management LLC	292,708	$5.25M	0.0%	-2.5%	0.391%
11/13/2023	E Fund Management Co. Ltd.	15,038	$0.27M	0.0%	-6.8%	0.020%

Data available starting January 2016

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Today's Range

Now: $14.84

$14.51

$14.94

50 Day Range

MA: $17.61

$14.83

$20.18

52 Week Range

Now: $14.84

$12.95

$25.47

Volume

839,454 shs

Average Volume

821,214 shs

Market Capitalization

$1.35 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81

Who are the company insiders with the largest holdings of Arcus Biosciences?: Arcus Biosciences' top insider shareholders include:
Gilead Sciences, Inc (Major Shareholder)
Juan C Jaen (President)
Jennifer Jarrett (COO)
Terry J Rosen (CEO)
Robert C Goeltz II (CFO)
Carolyn C Tang (General Counsel)
Alexander Azoy (CAO)
Learn More about top insider investors at Arcus Biosciences.
Who are the major institutional investors of Arcus Biosciences?: Arcus Biosciences' top institutional shareholders include:
Allspring Global Investments Holdings LLC — 0.01%
Diversified Trust Co — 0.01%
GAMMA Investing LLC — 0.00%
Learn More about top institutional investors of Arcus Biosciences stock.
Which major investors are buying Arcus Biosciences stock?: Within the last quarter, RCUS stock was acquired by institutional investors including:
Diversified Trust Co
Allspring Global Investments Holdings LLC
GAMMA Investing LLC